EPHESUS Post-MI Eplerenone Response Score

Clinical calculation support · Verify results before clinical use

Clinical eligibility and exploratory index

Enter post-MI clinical and laboratory values. This index is illustrative and is not a validated treatment-response prediction model.

—Index points
LVEF measured after the index MI.
For example, pulmonary rales or pulmonary venous congestion.

Clinical context

EPHESUS evaluated eplerenone in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure, with diabetes permitting enrollment without demonstrable heart-failure symptoms when LVEF criteria were met.

Core criteria represented in this tool

CriterionRule used
Timing after MI3–14 days
LVEF≤40%
Clinical conditionHeart-failure signs/symptoms OR diabetes
Trial laboratory exclusionsCreatinine >2.5 mg/dL or potassium >5.0 mEq/L were exclusion criteria

About the exploratory index

The original source code assigns illustrative points for LVEF category, diabetes, heart-failure signs, age >65 years, creatinine ≥2.0 mg/dL, and potassium ≥5.0 mEq/L. These weights are not a validated score, and the total must not be interpreted as an individual treatment-response probability or used to decide treatment.

References

Pitt B, Remme W, Zannad F, et al.Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med. 2003;348:1309–1321. DOI: 10.1056/NEJMoa030207.Read original EPHESUS trial
U.S. National Library of Medicine / DailyMed.INSPRA (eplerenone) prescribing information: contraindications, post-MI HFrEF dosing, and potassium monitoring.Read prescribing information
Clinical disclaimer: This tool is educational and does not replace the original trial criteria, current local prescribing information, or clinician judgment. Before starting eplerenone, assess potassium, renal function/creatinine clearance, blood pressure, interacting drugs (including CYP3A inhibitors), and the ability to monitor laboratory values. The exploratory point index is not validated and must not guide treatment decisions.